Category Ranking

98%

Total Visits

921

Avg Visit Duration

2 minutes

Citations

20

Article Abstract

Multisystem Inflammatory Syndrome in Children (MIS-C) is a severe complication of SARS-CoV-2 infection characterized by multi-organ involvement and inflammation. Testing of cellular function ex vivo to understand the aberrant immune response in MIS-C is limited. Despite strong antibody production in MIS-C, SARS-CoV-2 nucleic acid testing can remain positive for 4-6 weeks after infection. Therefore, we hypothesized that dysfunctional cell-mediated antibody responses downstream of antibody production may be responsible for delayed clearance of viral products in MIS-C. In MIS-C, monocytes were hyperfunctional for phagocytosis and cytokine production, while natural killer (NK) cells were hypofunctional for both killing and cytokine production. The decreased NK cell cytotoxicity correlated with an NK exhaustion marker signature and systemic IL-6 levels. Potentially providing a therapeutic option, cellular engagers of CD16 and SARS-CoV-2 proteins were found to rescue NK cell function in vitro. Together, our results reveal dysregulation in antibody-mediated cellular responses unique to MIS-C that likely contribute to the immune pathology of this disease.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11042288PMC
http://dx.doi.org/10.1101/2024.04.16.589585DOI Listing

Publication Analysis

Top Keywords

antibody-mediated cellular
8
cellular responses
8
multisystem inflammatory
8
inflammatory syndrome
8
syndrome children
8
children mis-c
8
antibody production
8
cytokine production
8
mis-c
7
responses dysregulated
4

Similar Publications

Extracorporeal photopheresis (ECP) is emerging as an apoptotic cell-based therapy that suppresses alloimmunity, promotes donor-specific regulation, and reduces the need for conventional maintenance immunosuppression. ECP therapy is associated with regulatory T-cell proliferation, anti-inflammatory effects, and reduction of anti-HLA antibodies, making ECP a possible alternative or adjunct treatment for preventing and treating transplant rejection. Presently, we have a limited understanding of the mechanisms of ECP action, and clinical evidence for efficacy in kidney transplantation is sparse.

View Article and Find Full Text PDF

Liver transplantation remains the definitive treatment for end-stage liver disease, yet rejection of the transplanted organ poses a significant challenge to long-term graft survival. We present a case of a 47-year-old woman who underwent liver transplantation for primary sclerosing cholangitis. Following the procedure, the patient experienced a rare phenomenon of dual rejection, characterized by both acute cellular rejection and antibody-mediated rejection.

View Article and Find Full Text PDF

Post-transplant rejection surveillance remains a cornerstone of heart transplant care. Although endomyocardial biopsy (EMB) has long been the gold standard for detecting rejection, its invasive nature, interobserver variability in histologic interpretation, and limitations in distinguishing between acute cellular rejection (ACR) and antibody-mediated rejection have prompted interest in noninvasive techniques. Traditional biomarkers- such as troponin, C-reactive protein, brain natriuretic peptide, and donor-specific antibodies- offer supplementary assessments of graft function but lack the specificity and sensitivity required to be standalone markers.

View Article and Find Full Text PDF

Background: Severe left ventricular/biventricular primary graft dysfunction (PGD-LV) continues to be a major contributor to 30-day mortality post-heart transplantation (HTx). In patients with severe PGD-LV, two distinctive presentation phenotypes are encountered: an "immediate PGD" (IP), where patients fail to wean from cardiopulmonary bypass (CPB), or a "delayed PGD" (DP) following successful weaning from CPB and/or transfer from the operating room. Data on these phenotypes' incidence, associated characteristics, and outcomes remain limited.

View Article and Find Full Text PDF

Gliomas are aggressive brain tumors of glial origin accounting for about 80% of the central nervous system (CNS) malignancies. Glioma cells are known to form a highly immunosuppressive tumor microenvironment (TME) capable of inhibiting T cell activation and protecting tumors from elimination by the immune system. One of the predominant immune inhibitory mechanisms in the TME are immune checkpoints: a complex system of membrane-bound ligands on tumor and immune cells that interact with surface receptors on T lymphocytes and affect their activation and cytotoxicity.

View Article and Find Full Text PDF